84 results about "C57BL/6" patented technology

The invention discloses an establishment method and application of a mouse gastric cancer orthotopic transplantation model, and the establishment method comprises the following steps: injecting a mouse gastric adenocarcinoma cell line MKC1 (Mus musculus) into a mouse gastric tissue, and feeding to obtain the mouse gastric cancer orthotopic transplantation model. Compared with the prior art, the mouse gastric cancer in-situ model established in the invention has the advantages of strong repeatability in the construction process and good passage stability, especially can form tumor subcutaneously in a C57BL / 6 mouse with a sound immune system, has a therapeutic response to immunotherapeutic drugs such as anti-PD-1 monoclonal antibody, and is suitable for research on gastric cancer immune microenvironment and drug resistance mechanism of immunotherapeutic drugs.

The invention provides application of a compound for regulating and controlling an METTL3 target spot in preparation of an anti-enterovirus drug, and belongs to the field of biological medicine, the compound is AN-465 / 42162872, and the compound has a relatively strong anti-EV71 effect in both in-vitro and in-vivo infection models. An in-vitro cell experiment, EV71 infected C57BL / 6 suckling mouse model, m6A methylation sequencing and other methods are utilized to research the activity and potential action mechanism of anti-EV71, and the result shows that AN-465 / 42162872 can inhibit duplication of EV71 in a human RD cell strain in a dose-dependent manner under the condition of maintaining relatively good cell activity, so that the application of AN-465 / 42162872 in the preparation of the EV71 drug is developed. The action mechanism is mainly as follows: the methylation level of the 5002 adenine in the 2C region of EV71 nucleic acid is remarkably reduced by regulating the METTL3, so that virus replication is inhibited, and the METTL3 has relatively high anti-EV71 drug utilization value.

The invention relates to the technical field of medicines and biology, in particular to a mouse EGFR (Epidermal Growth Factor Receptor) mutant lung adenocarcinoma cell line (EP Mus musculus) as well as preparation and application thereof. The invention provides an EP cell line ([EGFRE19delta (mutation); trp53 (deletion), EP] is derived from a lung adenocarcinoma model of a C57BL / 6 strain mouse, carries the most common EGFRE19del mutation in lung adenocarcinoma, is a first lung adenocarcinoma mouse cell line carrying EGFR mutation known in the world at present, has the in-vivo tumorigenesis ability of the C57BL / 6 strain mouse, and fills the blank of the mouse EGFR mutant cell line. The cell line provided by the invention has the background of EGFRE19del homozygous activation mutation and Trp53 homozygous deletion mutation, is sensitive to EGFR-TKI targeted therapy, can be used for in-situ tumor formation in subcutaneous and lung of an immune normal mouse C57BL / 6, and is suitable for immunotherapy and targeted therapy research of EGFR mutation lung adenocarcinoma.

The invention discloses an application of bulbus lilii glycoside B. The application is that bulbus lilii glycoside B is used as a unique active component or one of the active components to prepare a product for preventing or / and treating skin photoaging diseases. Experimental results of the invention show that lilium brownii glycoside B can significantly improve the cell viability of UVA-induced human skin fibroblasts, can reduce the number of beta-galactosidase positive cells in the UVA-induced human skin fibroblasts and reduce lipofuscin deposition, and can significantly improve the photoaging of the UVA-induced skin fibroblasts. Meanwhile, the skin photoaging grading of the back of a C57BL / 6 mouse induced by UVA can be remarkably improved. Therefore, the bulbus lilii glycoside B is expected to be used as an active ingredient for preparing medicines or cosmetics for preventing or / and treating the skin photoaging diseases, and particularly has important significance and remarkable application value for preventing or / and treating the UVA-induced skin photoaging diseases.

The present application provides a mouse model for studying microsatellite stable and unstable intestinal cancer. Specifically, the present application provides the use of a hybrid mouse in a reagent or kit for preparing a mouse model animal for constructing MSS type intestinal cancer and MSI-H type intestinal cancer, wherein the mouse is a F1 generation of C57BL / 6 x BALB / c. The mouse model of the present application provides the same genetic background for MSS type intestinal cancer cells and MSI-H type intestinal cancer cells, making the research of MSS type intestinal cancer and MSI-H type intestinal cancer more scientific.

This invention provides a method for constructing a fluorescently traced mouse model and its application in the sorting of Mcpt4-positive and negative mast cells. First, the Cre gene is knocked into the Mcpt4 gene sequence of C57BL / 6 mice using CRISPR / Cas9 technology. Then, through animal hybridization and Cre-loxP recombination technology, a fluorescently traced mouse model of Mcpt4-positive mast cells is obtained. The fluorescently traced mouse model possesses a dual-fluorescent reporter gene system consisting of the red fluorescent protein tdTomato and the green fluorescent protein ZsGreen. Mcpt4-positive mast cells exhibit red fluorescence, while other Mcpt4-negative cells exhibit green fluorescence. Using this fluorescently traced mouse model, Mcpt4-positive and negative mast cells can be rapidly, accurately, and effectively sorted, providing a reliable technical basis for exploring the roles and mechanisms of Mcpt4-positive and negative mast cells in immune responses.

The invention discloses an application of senkyunolide I in preparation of a medicine for treating hepatic fibrosis, which can obviously inhibit HSC (hepatic stellate cell) activation in vitro and evaluate the treatment effect of senkyunolide I on hepatic fibrosis in vivo by adopting a C57BL / 6 mouse hepatic fibrosis model induced by CCl4. The expression levels of liver alpha-smooth muscle actin, type I collagen and matrix metalloproteinase tissue inhibition factor 1 of individuals needing anti-hepatic fibrosis are obviously reduced in vivo and in vitro, and the hepatic fibrosis progress can be effectively intervened. Therefore, according to the application of the senkyunolide I in the hepatic fibrosis, the provided compound senkyunolide I has huge potential for inhibiting the hepatic fibrosis, an effective traditional Chinese medicine monomer component medicine is provided for treating the hepatic fibrosis, the new clinical adaptation application of the senkyunolide I is expanded, and the application prospect is good.

The application belongs to the technical field of biotechnology, and particularly relates to a colorectal cancer high liver metastasis cell line and a preparation method and application thereof. The cell line was preserved in the China Center for Type Culture Collection on January 14, 2026, and the preservation number is CCTCC NO: C202618. The cell line is derived from a mouse colorectal cancer cell line MC38, and is constructed by lentivirus transfection to express luciferase stably, and is obtained by continuously performing at least five rounds of liver metastasis tumor orthotopic iteration screening in C57BL / 6 mice through rectal submucosal injection. The MC38-P06 cell line provided by the application has a significantly enhanced liver metastasis ability, a shorter MC38-P01 model time, a higher liver tumor load, and a shorter mouse survival period, and can be used for screening and evaluating anti-liver metastasis drugs, researching liver microenvironment regulation mechanisms, and identifying liver metastasis related diagnostic markers.

The invention relates to an application of an aureomycin A derivative in preparation of an anti-tumor drug, the anti-tumor drug is a drug for preventing or treating liver cancer, and the aureomycin A derivative is selected from a compound shown as a formula (I), or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable ester or a pharmaceutically acceptable solvate of the compound. The aureomycin A derivative disclosed by the invention can be used for remarkably inhibiting the proliferation of liver cancer cells Hepa1-6, and the half inhibitory concentration (IC50 value) is 0.4821 mu g / mL and 0.1701 mu g / mL respectively; 11 days after administration, the tumor volume of a Hepa1-6 ectopic transplantation C57BL / 6 mouse is reduced, and the tumor weight of a Hepa1-6 tumor ectopic transplantation tumor is reduced; the aureomycin A derivative has the effects of remarkably inhibiting proliferation of liver cancer cells at the cellular level and remarkably reducing tumor growth of the liver cancer cells at the animal level, and a research direction is provided for development of new drugs.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

The invention discloses an application of a SUMO agonist N106 (the molecular formula is C17H14N4O3S, and the molecular weight is 354.38) in treatment or prevention of metabolic dysfunction related fatty liver disease (MASLD). The early-stage research of the invention finds that the liver SUMOylation level in MASLD clinical specimens and animal models is significantly reduced. In-vivo experiments show that in a high-fat diet induced C57BL / 6 mouse model, N106 (10mg / kg, intraperitoneal injection, once a day) can significantly improve liver lipid deposition and blood fat level of a high-fat diet mouse; in in-vitro experiments, N106 (10 mu M for 24 hours) can effectively reduce lipid droplet accumulation of HepG2 cells. The research reveals that N106 regulates lipid metabolism by activating an SUMOylation modification pathway for the first time, and a novel treatment strategy is provided for MASLD.

Embodiments of the present invention relate to the technical field of cell reprogramming, and disclose a reprogramming culture medium and a method for reprogramming chinchilla somatic cells into pluripotent stem cells. Among them, the culture medium includes culture medium I and culture medium II; culture medium I is a DMEM culture medium containing ≥5 v / v% serum substitute, ≥0.2 v / v% Nucleosides, ≥0.2 v / v% GlutaMax, 0.1 mM - 10.0 mM NEAA, 0.02 mM - 1 mM 2-mercaptoethanol, 1000 - 3000 U / mL LIF, 0.3 μM - 10 μM PD0325901, and 1 μM - 10 μM CHIR-99021; culture medium II is a complete culture medium for C57BL / 6 mouse embryonic stem cells. The method includes: reprogramming chinchilla somatic cells by transfecting transcription factors, and culturing the reprogrammed chinchilla somatic cells with culture medium I and culture medium II in sequence after transfection. By applying the technical solution of the present invention, chinchilla IPSCs can be successfully obtained.

The invention provides an anti-leukemia pharmaceutical composition based on DNA damage activated NKT cells and application of the anti-leukemia pharmaceutical composition. A mouse leukemia model is adopted as a research object, and experimental results show that in a C1498 homotransplantation tumor C57BL / 6 immune sound mouse leukemia model, the tumor inhibition rate of a daunorubicin and alpha-galactosylceramide combined treatment group reaches 67.4%, the survival time is remarkably prolonged, and obvious toxicity is not caused; in a C57 mouse leukemia model constructed by caudal vein injection of C1498, daunorubicin and alpha-galactosylceramide are combined to treat and reverse leukemia-related hepatosplenomegaly (the weight of liver and spleen is equivalent to that of a normal group), leukocyte proliferation is inhibited, and the survival state of mice is improved. The invention provides a new direction for treatment of leukemia.

The present invention belongs to the field of biomedical technology, and discloses the application of putrescine in the preparation of a drug for preventing and treating OHSS. Starting from the pathological mechanism of OHSS, an OHSS model was established with C57BL / 6 female mice, and putrescine was given through natural drinking water to explore its preventive and therapeutic effects on OHSS. The results showed that putrescine could reduce the ovarian weight, ovarian somatic ratio, number of congested follicles, number of corpora lutea, and VEGF expression level in the OHSS model, and would not have an adverse effect on the litter size of mice, indicating that putrescine can effectively prevent and treat OHSS. The present invention predicts to provide a new intervention approach and candidate drug for the clinical prevention of OHSS.

The invention discloses a construction method of a metabolism-related fatty liver disease and chronic hepatitis B-related hepatocellular carcinoma model, and belongs to the technical field of disease animal models. The construction method comprises the following steps: S1, linearizing an HBV genome, and injecting the linearized HBV genome into a fertilized egg of a C57BL / 6 mouse to establish an HBV transgenic mouse; and S2, feeding the HBV transgenic mouse in the step S1 with D09100310 feed to obtain the mouse model of metabolism-related fatty liver disease combined with chronic hepatitis B-related hepatocellular carcinoma. According to the construction method of the metabolism-related fatty liver disease combined chronic hepatitis B related hepatocellular carcinoma model, HBV-Tg mice are selected as experimental animals, the D09100310 mouse feed is utilized to construct the metabolism-related fatty liver disease combined chronic hepatitis B related hepatocellular carcinoma model, the stability and repeatability are good, objectiveness and simplicity are achieved, operability is high, and the model is suitable for being used for the clinical application. And other possible interference factors are reduced.

According to the method, the chiral gold nanoparticles with good biocompatibility are successfully prepared by finely controlling chemical reaction conditions. Meanwhile, a C57BL / 6 adult mouse is selected as an experimental subject, excitatory neurotoxin quinolinic acid is injected into a specific area of the brain of the mouse by adopting a stereotactic injection technology, and the Huntington's mouse model is successfully established. On the basis, the synthesized chiral gold nanoparticles are administered in an intravenous injection mode, and a PBS group and a tetrabenazine group are set as contrasts, so that the treatment effect of the chiral gold nanoparticles is evaluated. The prepared chiral gold nanoparticles can improve the structure of the cerebellum tissue of a mouse and relieve neurodegenerative diseases, a new thought and method are provided for treatment of the Huntington's disease, and the chiral gold nanoparticles have wide application prospects.

The invention relates to the technical field of tumor cell killing, in particular to a method for in-vivo detection of the tumor cell killing effect of NK cells, and the method comprises the following steps: S1, taking killing of male C57BL / 6 mouse NK cells on Hela cells and other types of human-derived tumor cells under in-vivo conditions as a model, and taking the Hela cells as a contrast; s2, grouping the selected mice, and correspondingly performing intraperitoneal injection of isotype IgG, an anti-NK1.1 antibody and an anti-mouse NKG2D monoclonal antibody; s3, preparing a cell mixed solution of to-be-detected tumor cells and Hela cells; s4, injecting the cell mixed liquid into the body of the mouse in a caudal vein injection manner; s5, killing each group of mice, and taking lungs to prepare a single-cell suspension; s6, detecting the number of CFSE positive cells and the number of PKH26 positive cells in the mouse lung single-cell suspension by adopting a flow cytometer; and S7, calculating the survival rate of the tumor cells to be detected. The method well solves the problem that the killing effect of the NK cells on the human tumor cells is difficult to accurately and truly evaluate in the prior art.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The invention discloses a high-efficiency C57BL / 6 mouse in-vitro fertilization method, relates to use of an in-vitro fertilization method in the technical field of biology, and particularly relates to a method for obtaining more high-quality fertilized eggs for gene editing in an in-vitro fertilization process of small animal gene editing model construction. Therefore, the animal cost of gene editing is greatly reduced, and wide application is promoted.

The invention discloses application of apolipoprotein H in preparation of drugs or health care products for preventing and / or treating alcoholic diseases. Researches show that an alcoholic hepatitis model is constructed by taking 10-week-old ApoH gene knockout mice (C57BL / 6ApoH- / -) as a background, a wild C57BL / 6 mouse alcoholic hepatitis model is taken as a contrast, peripheral blood transaminase and blood fat level, liver tissue fat content and liver tissue immunohistochemical staining are detected, and a result shows that the TC content of the liver tissue of the ApoH- / -mouse is obviously increased. The composition and content of bile acid in liver tissues and intestinal contents and the composition and abundance of intestinal flora are further detected, and results indicate that metabolic disorder of bile acid and disorder of intestinal flora exist. Based on the mechanism that low expression of alcoholic apolipoprotein H causes disorder of intestinal flora, affects bile acid metabolism and aggravates hepatic cell adiposis, the application is an accurate targeted therapeutic drug for treating alcoholic multi-organ injury.

The invention discloses an application of ilicin A in preparation of a medicine for preventing and treating ischemic heart disease, and belongs to the technical field of ilicin A. An experiment for improving heart functions of a mouse I / R model by the ilicin A is carried out, and male C57BL / 6 mice (with the age of 6-8 weeks; according to the method, 70 mice (the weight is 20 + / -2g) are bred in a constant-temperature and constant-humidity environment, the illumination / darkness period is 12 hours and lasts for one week, food and water are obtained without limitation, all male mice are randomly grouped as follows: a false operation group (n = 10), an I / R group (n = 15), an ilicin A group (30 and 60 mg / kg) and a captopril group (20 mg / kg), the mice in the ilicin A group and the captopril group are subjected to intragastric administration every day five days before the model is established, and the mice in the captopril group are subjected to intragastric administration every day. And the isopyknic contrast solution is applied to the false operation group and the I / R group.

The present invention discloses an application of a PAI-1 inhibitor in the preparation of a drug for treating liver ischemia-reperfusion injury, and relates to the field of biomedicine technology. The present invention selects PAI-1 gene knockout mice and C57BL / 6 wild-type mice as experimental subjects, constructs mouse liver ischemia-reperfusion injury models respectively, and studies the function of PAI-1 in liver ischemia-reperfusion injury. The study found that after PAI-1 knockout, it can reduce liver ischemia-reperfusion injury by affecting the formation and recruitment of liver neutrophil induction network, inhibiting the inflammatory response of the liver. PAI-1 is a key gene that affects neutrophil activation and is an important target for regulating inflammatory response during the reperfusion period. Animal experiments have verified that the PAI-1 specific inhibitor PAI-039 can reduce the degree of injury of mouse liver ischemia-reperfusion, providing new ideas for the development of new drugs for preventing, alleviating and / or treating tissue ischemia-reperfusion injury.

The invention provides a method for constructing a podocyte injury animal model, and belongs to the technical field of experimental animal models. The method specifically comprises the following steps: injecting miR-1 agomir twice a week through caudal veins of a male C57BL / 6 mouse for 7 times in total to obtain a podocyte injury animal model; the miR-1 with high expression of skeletal muscle tissue is used for inducing podocyte damage, interference of damage of other organs and cells is reduced, and the miR-1 plays an important role in research on pathogenesis of chronic kidney diseases.

The invention relates to application of tectoridin in preparation of a medicine for treating radiation-induced lung injury. According to the invention, the influence of tectoridin on radiation-induced lung injury is researched by constructing a C57BL / 6 mouse radiation-induced lung injury model; research results prove that the exogenous irisin can relieve alveolar interstitial thickening, hyperemia, pulmonary edema, alveolar collapse, airway wall thickening, airway cavity narrowing and increase of collagen deposition around the airway caused by radiation; besides, the tectoridin obviously reduces lung tissue inflammatory factor synthesis and release, inflammatory cell infiltration and oxidative stress caused by radiation, and obviously reduces lung tissue fibrosis and lung tissue function barrier caused by radiation, the effect of the tectoridin in resisting radiation-induced lung injury is further proved, research and application of the tectoridin are broadened, and the application range of the tectoridin in resisting radiation-induced lung injury is widened. Meanwhile, a new target spot and a new visual field are provided for treating the radiation-induced lung injury.

The invention relates to a traditional Chinese medicine composition for treating lung cancer and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-20% of red ginseng, 10-20% of radix glehniae, 10-20% of rhizoma arisaematis, 10-40% of coix seeds, 5-10% of gecko, 5-10% of toad skin, 10-20% of black nightshade and 10-20% of Based on animal experiments of a mouse lung cancer transplantation tumor model, the traditional Chinese medicine composition has remarkable tumor inhibition and immunoregulation effects, can remarkably prolong the lifetime of a C57BL / 6 lung cancer mouse, remarkably inhibit tumor growth, improve the proportion of CD4 + and CD8 + T cells of the spleen, increase the proportion of dendritic cells (DC) in a tumor microenvironment and reduce the proportion of myeloid-derived suppressor cells (PMN-MDSC), and can be used for preparing a medicine for treating the lung cancer. The curative effect is prominent.

The invention relates to the technical field of bioengineering, and particularly discloses a construction method and application of a mixed type liver cancer mouse model, pCMV-Cre, pT3-EF1 alphaH-c-Met, pT3-EF1 alphaH-N90-beta-catenin plasmids and pCMV (CAT) T7-SB100 transposase are mixed to prepare an injection, and the injection is injected into a C57BL / 6-MFN1flox / flox mouse at the age of 6 weeks in a caudal vein mode to obtain the mixed type liver cancer mouse model. The construction method of the mixed type liver cancer mouse model is stable, reliable, efficient and easy to implement, and the constructed mixed type liver cancer mouse model can be used for exploring the generation and development mechanism of the mixed type liver cancer and researching treatment targets and can also be used for screening drugs for treating the mixed type liver cancer.

The invention discloses a CAR-T cell for overexpressing H2A. Z as well as a preparation method and application of the CAR-T cell. In particular, the present invention provides a chimeric antigen receptor comprising an H2A. Z gene or a variant having the same function as the H2A. Z gene. The chimeric antigen receptor further comprises a signal peptide, a CLDN18.2-targeted antigen binding structural domain, a hinge region, a transmembrane region, a co-stimulation structural domain and an intracellular signal transduction structural domain. In a C57BL / 6 mouse model inoculated with CLDN18.2 positive tumor cells MC38-CLDN18.2 and KPC, the treatment effect of the CLDN18.2-CAR-T cell for overexpressing the H2AZ.1 gene disclosed by the invention is obviously superior to that of a CLDN18.2-CAR-T control group without overexpressing the H2AZ.1 gene.

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The invention relates to the field of biological medicines, in particular to a preparation method of a novel black soybean hull extract and application of the black soybean hull extract in preparation of a medicine for treating Alzheimer's disease. The preparation method of the black soybean hull extract does not need toxic organic solvent extraction, is different from only extraction of black soybean hull anthocyanin, can reserve active ingredients of black soybean seed coats to the maximum extent, improves the yield and extraction efficiency of a final compound product, and reduces toxic substances possibly generated in the preparation process. Wild C57BL / 6 mice and disease model APP / Ps1 mice are utilized to research the influence of the black soybean hull extract on the Alzheimer's disease. Compared with disease model mice fed with standard mixed grain feed, the black soybean hull extract is added into diet, so that the learning and memory ability and the movement ability of the disease model mice can be remarkably improved, and the anxiety degree of the disease model mice is reduced. Therefore, the black bean peel extract has a remarkable treatment effect on the Alzheimer's disease. The black bean peel extract has the following advantages in the aspect of treating the Alzheimer's disease: the natural plant extract is non-toxic and has no side effect; raw materials are easily available and the preparation cost is low; the diet intake is convenient and practical. The black soybean hull extract has important scientific significance and application value for treating the Alzheimer's disease.